Your browser doesn't support javascript.
Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity.
Chen, Shuxiong; Evert, Benjamin; Adeniyi, Adetayo; Salla-Martret, Mercè; Lua, Linda H-L; Ozberk, Victoria; Pandey, Manisha; Good, Michael F; Suhrbier, Andreas; Halfmann, Peter; Kawaoka, Yoshihiro; Rehm, Bernd H A.
  • Chen S; Centre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.
  • Evert B; Centre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.
  • Adeniyi A; Protein Expression Facility, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Salla-Martret M; Protein Expression Facility, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Lua LH; Protein Expression Facility, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Ozberk V; Institute for Glycomics, Griffith University, Gold Coast, QLD, 4215, Australia.
  • Pandey M; Institute for Glycomics, Griffith University, Gold Coast, QLD, 4215, Australia.
  • Good MF; Institute for Glycomics, Griffith University, Gold Coast, QLD, 4215, Australia.
  • Suhrbier A; QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
  • Halfmann P; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53706, USA.
  • Kawaoka Y; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53706, USA.
  • Rehm BHA; Centre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.
Adv Healthc Mater ; 11(3): e2102089, 2022 02.
Article in English | MEDLINE | ID: covidwho-1487433
ABSTRACT
There is an unmet need for safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are stable and can be cost-effectively produced at large scale. Here, a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS-CoV-2 is used. Coronavirus antigen-coated BPs are described as vaccines against SARS-CoV-2. The spike protein subunit S1 or epitopes from S and M proteins (SM) plus/minus the nucleocapsid protein (N) are selected as antigens to either coat BPs during assembly inside engineered Escherichia coli or BPs are engineered to specifically ligate glycosylated spike protein (S1-ICC) produced by using baculovirus expression in insect cell culture (ICC). BP vaccines are safe and immunogenic in mice. BP vaccines, SM-BP-N and S1-ICC-BP induced protective immunity in the hamster SARS-CoV-2 infection model as shown by reduction of virus titers up to viral clearance in lungs post infection. The BP platform offers the possibility for rapid design and cost-effective large-scale manufacture of ambient temperature stable and globally available vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Adv Healthc Mater Year: 2022 Document Type: Article Affiliation country: Adhm.202102089

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Adv Healthc Mater Year: 2022 Document Type: Article Affiliation country: Adhm.202102089